++
1.2.8: Develop and implement individualized treatment plans, taking into consideration contraindications, warnings, and precautions
++
++
+
What is the parenteral asthma medication contraindicated in patients with a corn allergy?
++
++
+
++
+
++
+
++
+
+
++
+
Theophylline (B) is contraindicated in patients with a corn allergy. The premixed injection may contain corn-derived dextrose.
+
Prednisone (A), budesonide (C), and omalizumab (D) are not contraindicated in patients with a corn allergy.
++
++
+
Which of the following conditions would be a contraindication to administration of tamoxifen for the prevention of breast cancer in a "high-risk" premenopausal patient?
++
++
+
(A) History of deep venous thrombosis
++
+
(B) First-degree relative with ER negative breast cancer
++
+
(C) History of diabetes mellitus
++
+
+
++
+
Tamoxifen is associated with an increased risk for developing thromboembolic events. Administration of tamoxifen to prevent breast cancer is contraindicated in patients with a history of deep venous thrombosis (A) or pulmonary emboli.
+
The estrogen receptor status of first-degree relatives is not a contraindication to prescribing tamoxifen to reduce the risk of developing breast cancer (B). Diabetes mellitus (C) is not a contraindication to prescribing tamoxifen to reduce the risk for developing breast cancer. A history of seizures (D) is not a contraindication to prescribing tamoxifen to reduce the risk for developing breast cancer.
++
++
+
Which of the following conditions would be a contraindication for prescribing an aromatase inhibitor?
++
++
+
(A) The development of arthralgias and myalgias
++
+
(B) A patient with a history of thromboembolic events
++
+
(C) A premenopausal patient
++
+
(D) A postmenopausal patient with a history of thromboembolic events
+
++
+
The administration of aromatase inhibitors to premenopausal women (C) with breast cancer is contraindicated because they are ineffective in depleting estrogen production in women with functioning ovaries.
+
Arthralgias and myalgias (A) are documented adverse effects of aromatase inhibitors. If a patient develops these toxicities, a trial of an alternative aromatase inhibitor is indicated. A patient with a history of thromboembolic events (B) is not a contraindication for administration of aromatase inhibitors. The administration of aromatase inhibitors are not contraindicated for postmenopausal patients with a history of thromboembolic events (D).
+
++
++
+
Aldosterone antagonists should be avoided in ...